Skip to content
MedsAcross

Medicine

Augmentin 125 mg/31.25 mg per 5 mL powder for oral suspension

Amoxicillin and Clavulanate · Oral · Allegis Holdings
Available on requestPrescription onlyUS FDA

Augmentin 125 mg/31.25 mg per 5 mL powder for oral suspension is a prescription medicine containing Amoxicillin and Clavulanate for oral use, marketed by Allegis Holdings, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store dry powder at or below 25°C (77°F). Store reconstituted suspension under…

Key facts

Active ingredient (INN)
Amoxicillin and Clavulanate
Brand
Augmentin
Strength
125 mg/31.25 mg per 5 mL
Dosage form
Powder for oral suspension
Route
Oral
Packs
75 mL, 100 mL, 150 mL
Marketing authorisation holder
Allegis Holdings
Manufacturer
Allegis Holdings
Origin register
US FDA, United States
Storage
Store dry powder at or below 25°C (77°F). Store reconstituted suspension under refrigeration.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.10Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
1 September 2023
Identifiers
RxCUI 617302, 617333DailyMed set ID 04a31a42-d79e-bbb4-e063-6394a90a63eeNDC 71297-240Application NDA050575

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
75 mL in 1 bottle71297-240-34Allegis Holdings20 February 2024
100 mL in 1 bottle71297-240-35Allegis Holdings1 September 2023
150 mL in 1 bottle71297-240-36Allegis Holdings1 September 2023

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 6 August 1984Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Amoxicillin and Clavulanate 125 mg/31.25 mg per 5 mL powder for oral suspension.

Compare 1

Other strengths and forms of Amoxicillin and Clavulanate

Clinical summary

Amoxicillin and Clavulanate is a fixed-dose combination of a penicillin-class antibacterial and a beta lactamase inhibitor indicated for the treatment of infections in adults and pediatric patients, among other approved uses. MedsAcross supplies Amoxicillin and Clavulanate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Amoxicillin and Clavulanate

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Augmentin 125 mg/31.25 mg per 5 mL powder for oral suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.